Chemokines as molecular targets for therapeutic intervention

被引:44
作者
Howard, OMZ [1 ]
Oppenheim, JJ
Wang, JM
机构
[1] NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, Div Basic Sci, Frederick, MD 21701 USA
[2] SAIC Frederick, IRSP, Frederick, MD USA
关键词
chemokines; chemokine receptors; antagonists;
D O I
10.1023/A:1020587407535
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Despite the youth of the chemokine field, many antagonists of chemokine function have already been identified and tested at the preclinical level. These include neutralizing antibodies, peptidyl and non-peptidyl antagonists and non-specific immunosuppressive agents. These early studies suggest that chemokine agonists have the potential to regulate many diseases, ranging from HIV-1 infection and tumor growth to acute and chronic inflammation. Clinical application will depend on pharmaceutical development. Great strides have been made in defining structural domains of the chemokines involved in receptor binding and activation. The identification of receptors is rapidly progressing, but with 50 potential ligands and 15 characterized receptors, it is obvious that additional molecular studies are needed. The intriguing observation that several pathogens either use chemokine receptors as entry portals or produce chemokine decoys to subvert the immune system suggests that there is much to be learned about the immune system from studies of "virokines." Future studies should lead to the discovery and design of more effective inhibitors and antagonists with therapeutic benefit.
引用
收藏
页码:280 / 292
页数:13
相关论文
共 99 条
[1]   Chemoattractant receptor cross-desensitization [J].
Ali, H ;
Richardson, RM ;
Haribabu, B ;
Snyderman, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (10) :6027-6030
[2]   Release of RANTES from nasal and bronchial epithelial cells [J].
Altman, GB ;
Altman, LC ;
Luchtel, DL ;
Jabbour, AJ ;
Baker, C .
CELL BIOLOGY AND TOXICOLOGY, 1997, 13 (03) :205-213
[3]   Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice [J].
Arenberg, DA ;
Kunkel, SL ;
Polverini, PJ ;
Glass, M ;
Burdick, MD ;
Strieter, RM .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (12) :2792-2802
[4]   Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: Synergism with prostanoids and salbutamol [J].
Au, BT ;
Teixeira, MM ;
Collins, PD ;
Williams, TJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (06) :1260-1266
[5]   A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].
Baba, M ;
Nishimura, O ;
Kanzaki, N ;
Okamoto, M ;
Sawada, H ;
Iizawa, Y ;
Shiraishi, M ;
Aramaki, Y ;
Okonogi, K ;
Ogawa, Y ;
Meguro, K ;
Fujino, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703
[6]  
BADOLATO R, 1995, J IMMUNOL, V155, P4004
[7]   Chemokines and leukocyte traffic [J].
Baggiolini, M .
NATURE, 1998, 392 (6676) :565-568
[8]  
Baly DL, 1998, J IMMUNOL, V161, P4944
[9]   Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy [J].
Chen, JD ;
Bai, XF ;
Yang, AG ;
Cong, YP ;
Chen, SY .
NATURE MEDICINE, 1997, 3 (10) :1110-1116
[10]   NEW SULFONATED DISTAMYCIN-A DERIVATIVES WITH BFGF COMPLEXING ACTIVITY [J].
CIOMEI, M ;
PASTORI, W ;
MARIANI, M ;
SOLA, F ;
GRANDI, M ;
MONGELLI, N .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (02) :295-302